September 12, 2018
No significant differences in all-cause mortality were observed between treatments in the BP-lowering group.
Atorvastatin- and amlodipine-based antihypertensive treatments are associated with significant long-term reductions in cardiovascular death and stroke death, respectively, in patients with hypertension, with mortality benefits observed beyond 10 years of treatment, according to a study presented at the European Society of Cardiology in Munich, Germany, and simultaneously published in the Lancet.
In the 16-year follow-up of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy, researchers evaluated the long-term mortality outcomes of patients with hypertension who received calcium channel blocker-based treatments and lipid-lowering statin therapies. Patients based in the United Kingdom were followed for a median of 15.7 years (interquartile range, 9.7-16.4 years), and all-cause and cardiovascular mortality outcomes were recorded.
Participants who enrolled in the blood pressure-lowering group were randomly assigned to either amlodipine-based (n=4305) or atenolol-based blood pressure-lowering treatment (n=4275). Those in the blood pressure-lowering group with a total cholesterol level ≤6.5 mmol/L and no history of lipid-lowering therapy were then randomly assigned to either atorvastatin (n=2317) or placebo (n=2288) in the lipid-lowering study group (LLA). All other patients were allocated to the non-LLA group.